Phase 1b Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 22 May 2018
At a glance
- Drugs Sapanisertib (Primary) ; Letrozole
- Indications Breast cancer
- Focus Adverse reactions
- 10 Jun 2017 Biomarkers information updated
- 08 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Dec 2019.
- 08 May 2017 Status changed from not yet recruiting to recruiting.